Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Derek Sheader
Latest news
-
LifeArc announces partnership with Elpida Therapeutics to accelerate gene therapies for ultra-rare diseases in children
-
LifeArc Translational Science Summit 2026: Charting new paths for rare disease
-
From curiosity to career: LifeArc placement students share their stories for British Science Week